0A9G Stock Overview A biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Mereo BioPharma Group plc Competitors Price History & Performance
Summary of share price highs, lows and changes for Mereo BioPharma Group Historical stock prices Current Share Price US$3.36 52 Week High US$5.01 52 Week Low US$2.19 Beta 0.91 1 Month Change -10.79% 3 Month Change -17.98% 1 Year Change 57.10% 3 Year Change 108.88% 5 Year Change n/a Change since IPO 6.63%
Recent News & Updates Mereo BioPharma Group plc has filed a Follow-on Equity Offering in the amount of $49.999887 million. Jun 15
Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc Announce Positive 14-Month Results from the Phase 2 Portion of the Ongoing Phase 2/3 Orbit Study Jun 13
Mereo BioPharma Group plc, Annual General Meeting, May 23, 2024 Apr 26
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI) Oct 16
Ultragenyx Pharmaceutical Inc. Announces Data from the Dose- Selection Phase 2/3 Orbit Study Jun 07
Mereo BioPharma Group plc Presents Phase 2 Data from “ASTRAEUS” Trial of Its Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease at the 2023 American Thoracic Society International Conference May 24 See more updates Mereo BioPharma Group plc has filed a Follow-on Equity Offering in the amount of $49.999887 million. Jun 15
Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc Announce Positive 14-Month Results from the Phase 2 Portion of the Ongoing Phase 2/3 Orbit Study Jun 13
Mereo BioPharma Group plc, Annual General Meeting, May 23, 2024 Apr 26
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI) Oct 16
Ultragenyx Pharmaceutical Inc. Announces Data from the Dose- Selection Phase 2/3 Orbit Study Jun 07
Mereo BioPharma Group plc Presents Phase 2 Data from “ASTRAEUS” Trial of Its Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease at the 2023 American Thoracic Society International Conference May 24
Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement May 09
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market May 08
Less than half of directors are independent Nov 16
Mereo BioPharma Receives Notification of Nasdaq Minimum Bid Price Deficiency Nov 03
Mereo Biopharma Group plc Announces Board Changes Oct 29
Rubric Capital Management LP Comments on Mereo BioPharma Group Plc Updated Operating Plan Oct 19
Mereo BioPharma Group plc Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease Oct 18
Less than half of directors are independent Oct 11
Less than half of directors are independent Sep 20
Rubric Capital Management LP Issues a Letter to the Shareholders of Mereo BioPharma Group plc Sep 16
Rubric Capital Management LP Issues a Letter to the Shareholders of Mereo BioPharma Group plc Sep 15
Mereo Biopharma Group plc Reports Clinical Update and Interim Biomarker Analysis Presented At Esmo 2022 from Activate Phase 1B/2 Open Label Study of Etigilimab (Anti-Tigit Antibody Mph-313) Plus Nivolumab (Anti-Pd-1 Antibody) in Solid Tumors Sep 13
Investor sentiment deteriorated over the past week Sep 06
Rubric Capital Management LP Delivers a Letter to Mereo BioPharma Group Aug 25
Mereo BioPharma Group plc Announces Board Changes Aug 23
Investor sentiment deteriorated over the past week Jul 29
Investor sentiment improved over the past week Jul 12
Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement Jul 06
Astrazeneca Reportedly Considering Take over Offer for Mereo Jun 18
Investor sentiment improved over the past week Jun 17
Rubric Capital Sends Letter to Mereo BioPharma Jun 10
Mereo BioPharma Group plc to Present Data Update for the Phase 1B/2 Study (Activate) of Etigilimab and Nivolumab At 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan Jun 03
High number of new directors Jun 02
High number of new directors May 31
Rubric Capital Discloses its Views on Mereo BioPharma May 29
Mereo BioPharma Receives Notification of Nasdaq Minimum Bid Price Deficiency May 27 Mereo BioPharma Group plc Announces Board Changes Mereo BioPharma Group plc Announces Positive Top-Line Efficacy and Safety Data from “Astraeus” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Emphysema May 10
Investor sentiment deteriorated over the past week Apr 08
Mereo BioPharma Group plc Announces Appointment of Anne Hyland to Board of Directors Mar 03
The University of Alabama at Birmingham and Mereo BioPharma Group plc, Announces Positive Top-Line Results from “Costa” A Phase 1B/2 Trial of Alvelestat in Hospitalized Patients with Covid-19 Respiratory Disease Dec 23
Mereo Biopharma Group plc to Present Biomarker Data from Phase 1B/2 Investigator-Sponsored Trial of Alvelestat in Bronchiolitis Obliterans Syndrome at the ASH Annual Meeting Dec 15
High number of new directors Nov 01
High number of new directors Oct 02
Mereo BioPharma Announces Positive Desmosine Biomarker Data from an Interim Analysis of an Investigator Initiated Study of alvelestat in Bronchiolitis Obliterans Syndrome (BOS) Jun 03
Forecast to breakeven in 2025 May 27 Shareholder Returns 0A9G GB Biotechs GB Market 7D -9.1% -5.1% -2.2% 1Y 57.1% -24.5% 2.4%
See full shareholder returns
Return vs Industry: 0A9G exceeded the UK Biotechs industry which returned -24.5% over the past year.
Return vs Market: 0A9G exceeded the UK Market which returned 2.4% over the past year.
Price Volatility Is 0A9G's price volatile compared to industry and market? 0A9G volatility 0A9G Average Weekly Movement 9.6% Biotechs Industry Average Movement 7.0% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.5% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0A9G's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0A9G's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials.
Show more Mereo BioPharma Group plc Fundamentals Summary How do Mereo BioPharma Group's earnings and revenue compare to its market cap? 0A9G fundamental statistics Market cap US$518.91m Earnings (TTM ) -US$45.32m Revenue (TTM ) US$1.00m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0A9G income statement (TTM ) Revenue US$1.00m Cost of Revenue -US$273.00k Gross Profit US$1.27m Other Expenses US$46.59m Earnings -US$45.32m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.29 Gross Margin 127.30% Net Profit Margin -4,531.60% Debt/Equity Ratio 7.7%
How did 0A9G perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 06:43 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Mereo BioPharma Group plc is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jack Allen Baird Yun Zhong BTIG Julian Harrison BTIG
Show 6 more analysts 